ongoing trials trial from www.clinicaltrials.gov Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta Year: 2025 Date: 2025 Author: Source https://clinicaltrials.gov/study/NCT07108153 Study design (if review, criteria of inclusion for studies) Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT Participants ADULT, OLDER_ADULT with CF Interventions DRUG: SION-719|DRUG: Placebo-to-match SION-719 Outcome measures Adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed Trikafta